Marshall Wace
MDNA

Marshall Wace’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Marshall Wace’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-80,401
Closed -$328K – 3255
2021
Q1 		$328K Buy
+80,401
New +$327K ﹤0.01% 2100

Other funds holding MDNA

AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Marshall Wace's MDNA Position: Q2 2021 in Review

Marshall Wace sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q2 2021, closing a stake of 80,401 shares — an estimated $328K sold.

Marshall Wace first reported a position in MDNA in Q1 2021 and held it in 1 quarter. The position peaked at $328K in Q1 2021. 26 funds tracked by Wall St. Rank hold MDNA as of Q2 2021.

  • Marshall Wace reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 80,401 Medicenna Therapeutics Corp. Common Shares shares in Q2 2021, an estimated $328K.
  • Marshall Wace first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 1 quarter.
  • Marshall Wace's Medicenna Therapeutics Corp. Common Shares position peaked at $328K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.